Regeneron Pharmaceuticals Inc. (REGN) and KalVista Pharmaceuticals Inc. (NASDAQ:KALV) Comparison side by side

Since Regeneron Pharmaceuticals Inc. (NASDAQ:REGN) and KalVista Pharmaceuticals Inc. (NASDAQ:KALV) are part of the Biotechnology industry, they are influenced by compare. The influences particularly affect the dividends, analyst recommendations, profitability, risk, institutional ownership, earnings and valuation of both companies.

Earnings & Valuation

Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio
Regeneron Pharmaceuticals Inc. 6.71B 6.63 2.44B 20.71 20.95
KalVista Pharmaceuticals Inc. 16.48M 27.41 14.22M -1.23 0.00

Table 1 highlights Regeneron Pharmaceuticals Inc. and KalVista Pharmaceuticals Inc.’s top-line revenue, earnings per share and valuation.


Table 2 provides the net margins, return on equity and return on assets of the two firms.

Net Margins Return on Equity Return on Assets
Regeneron Pharmaceuticals Inc. 36.36% 32.2% 23.4%
KalVista Pharmaceuticals Inc. -86.29% -30.1% -17.9%

Risk and Volatility

Regeneron Pharmaceuticals Inc. has a beta of 1.2 and its 20.00% more volatile than Standard & Poor’s 500. Competitively, KalVista Pharmaceuticals Inc.’s beta is 2.46 which is 146.00% more volatile than Standard & Poor’s 500.


The current Quick Ratio of Regeneron Pharmaceuticals Inc. is 3.9 while its Current Ratio is 4.5. Meanwhile, KalVista Pharmaceuticals Inc. has a Current Ratio of 6.2 while its Quick Ratio is 6.2. KalVista Pharmaceuticals Inc. is better positioned to pay off its short-term and long-term debts than Regeneron Pharmaceuticals Inc.

Analyst Recommendations

The table shown features the ratings and recommendations for Regeneron Pharmaceuticals Inc. and KalVista Pharmaceuticals Inc.

Sell Ratings Hold Ratings Buy Ratings Rating Score
Regeneron Pharmaceuticals Inc. 0 5 2 2.29
KalVista Pharmaceuticals Inc. 0 0 0 0.00

Regeneron Pharmaceuticals Inc. has a consensus target price of $436.33, and a 6.68% upside potential.

Institutional and Insider Ownership

Roughly 72.7% of Regeneron Pharmaceuticals Inc. shares are held by institutional investors while 82.2% of KalVista Pharmaceuticals Inc. are owned by institutional investors. 0.9% are Regeneron Pharmaceuticals Inc.’s share held by insiders. On the other hand, insiders held about 2.9% of KalVista Pharmaceuticals Inc.?s shares.


Here are the Weekly, Monthly, Quarterly, Half Yearly, Yearly and YTD Performance of both pretenders.

Performance (W) Performance (M) Performance (Q) Performance (HY) Performance (Y) Performance (YTD)
Regeneron Pharmaceuticals Inc. 3.2% 1.06% 19.3% 6.69% 34.82% 16.15%
KalVista Pharmaceuticals Inc. 2.29% 21.99% -0.57% 39.88% 120.29% 15.44%

For the past year Regeneron Pharmaceuticals Inc.’s stock price has bigger growth than KalVista Pharmaceuticals Inc.


On 10 of the 12 factors Regeneron Pharmaceuticals Inc. beats KalVista Pharmaceuticals Inc.

Regeneron Pharmaceuticals, Inc., a biopharmaceutical company, discovers, invents, develops, manufactures, and commercializes medicines for the treatment of serious medical conditions worldwide. Its products include EYLEA injection for the treatment of neovascular age-related macular degeneration, diabetic macular edema, and macular edema following retinal vein occlusion; Praluent injection, an adjunct to diet and tolerated statin therapy for the treatment of adults with heterozygous familial hypercholesterolemia or clinical atherosclerotic cardiovascular disease; and ARCALYST injection for the treatment of cryopyrin-associated periodic syndromes, including familial cold auto-inflammatory syndrome and muckle-wells syndrome in adults and children’s. It also markets Kevzara injection for the treatment of rheumatoid arthritis in adults; and ZALTRAP, an injection for intravenous infusion, which is used in combination with 5-fluorouracil, leucovorin, and irinotecan for the treatment of metastatic colorectal cancer. The company also develops EYLEA, trap-based clinical product that is in Phase III study for the treatment of neovascular glaucoma. Regeneron Pharmaceuticals, Inc. has collaboration agreement with Sanofi for the development of antibody-based clinical products comprising Praluent, Sarilumab, Dupixent, REGN2810, REGN3500, and REGN3767; Bayer HealthCare LLC for the development of Nesvacumab/aflibercept, which is used in ophthalmology; and with Teva and Mitsubishi Tanabe Pharma Corporation for developing Fasinumab, an antibody to nerve growth factor. It also has collaboration agreements with Intellia Therapeutics, Inc. to advance CRISPR/Cas gene-editing technology for in vivo therapeutic development; and the U.S. Department of Health and Human Services to develop treatments combating infectious diseases. The company was founded in 1988 and is headquartered in Tarrytown, New York.

KalVista Pharmaceuticals, Inc., a clinical stage pharmaceutical company, discovers, develops, and commercializes small molecule protease inhibitors. The company’s product portfolio comprises small molecule plasma kallikrein inhibitors targeting hereditary angioedema (HAE) and diabetic macular edema (DME); and oral plasma kallikrein inhibitors. Its products under development include KVD818, an orally delivered molecule that is in Phase I clinical trial for the treatment of HAE; KVD001, an intravitreally administered plasma kallikrein inhibitor that has completed a Phase I clinical trials for the treatment of DME; and KVD900, a potent inhibitor of plasma kallikrein that is in preclinical safety studies for use against human proteases related to plasma kallikrein. The company is headquartered in Cambridge, Massachusetts.